Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449514
Status:
UNKNOWN
Last Update Posted:
2007-09-20
First Post:
2007-03-18
Brief Title:
Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
Sponsor:
Shaare Zedek Medical Center
Organization:
Shaare Zedek Medical Center
Study Overview
Official Title:
Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate
Status:
UNKNOWN
Status Verified Date:
2007-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
About 10-15 of all couples attempting to conceive will not become pregnant within one year Among those the majority will have ovulatory dysfunction mild male infertility or unexplained infertility The traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate Probably due to anti-estrogenic effects of this agent will some patients will have a thin endometrium as measured by sonography at the time of ovulation This phenomenon may be associated with a lower chance to conceive Tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction Preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None